指数放量大跌，市场成交量达到3.1万亿，相较于昨天放量7500亿，而市场大跌，也就意味着，这波新冲进来的资金悉数套牢，今天这波大跌，主要还是 银行证券等权重股砸盘，上午反弹的方向其实跟美联储降息关系不大，因为降息直接利好的有色和金融早盘就开始大跌，而上午指数冲击3900点的主要原 因还是受到国产替代消息的影响。 。 美联储降息靴子落地，大盘冲高回落午后开始跳水！ 从技术走势来看，今天指数可能会在金融的带动下走出调整的走势，重点关注30分钟级别的20均线3860点的支撑，从今天来看，指数在午后的跳水已经跌 破，所以今天适当减仓，更重要的是收盘指数已经来到3830点，还跌破了日线级别的20日均线的支撑，代表指数中期也有走弱的趋势，明天市场如果不能 重回20日均线上方，指数可能走出继续调整的走势。 但当上午指数反弹的过程中成交量其实并没有明显放大，而且相关消息早在上周就已经有所传闻，所以当寒王等科技股再度爆发引爆市场情绪后，由于仅 仅是消息面的刺激，午后在科技金融等权重的带动下指数迎来跳水。 。 ...

Global investment firm GQG Partners has issued a stark warning that the current technology market is exhibiting “dotcom-era overvaluation,” with a combination of soaring capital spending and weakening fundamentals that could lead to repercussions more pronounced than the 1999 crash.Current Conditions More Fragile Than Dotcom Bubble?In a new research report titled “Dotcom on Steroids,” the firm argues that the AI-driven boom has pushed the tech sector to a dangerous inflection point, masking underlying risks ...

Group 1: Stock Purchases and Reactions - FBI Director Kash Patel faced backlash for purchasing $15,001–$50,000 worth of Krispy Kreme (NASDAQ: DNUT) and $50,001–$100,000 worth of ON Semiconductor (NASDAQ: ON) shares in May 2023 [1][4] - Following Patel's remarks, Krispy Kreme shares spiked by as much as 11.5% intraday but closed up only 0.96%, remaining down over 67% year-to-date [8] - ON Semiconductor also experienced a brief spike but ended the day with less than 1% increase [8] Group 2: Conflict of Interest and Legislative Response - Patel has sold off numerous positions, including significant sales in Nvidia (NASDAQ: NVDA), Palantir (NYSE: PLTR), and others, to avoid conflict of interest [4][5] - Lawmakers are pushing bipartisan efforts to prohibit members of Congress and high-ranking officials from trading individual securities, with Patel agreeing to collaborate on the bill [5] - Patel's investment in a company controlling Shein, a Chinese e-commerce giant, raised concerns about conflicts given China's status as a primary security threat [6]

Group 1 - A class action was filed on behalf of stockholders who purchased or acquired Quantum Corporation securities between November 15, 2024, and August 18, 2025 [1]

Summary of Key Points from the Conference Call Industry Overview - The focus is on the **hyperscaler industry**, which includes major companies like **Amazon (AMZN)**, **Google (GOOGL)**, **Meta (META)**, **Microsoft (MSFT)**, and **Oracle (ORCL)**. [9][12][22] Core Insights - **Capex Trends**: Hyperscalers are experiencing an unprecedented investment cycle, with capex-to-sales ratios projected to rise to approximately **26% by 2027**, nearing the **32% peak** seen during the dot-com era and surpassing levels from the shale fracking boom. [7][12][14] - **Investment Commitments**: Significant amounts of AI investment are already committed, with **AI Enabler capex** expected to reach **$450 billion in 2025**, **$520 billion in 2026**, and **$540 billion in 2027**. [7][30] - **Finance Leases**: The growing reliance on finance leases is not fully captured in traditional capex figures, which may understate the true scale of investment. [4][38] - **Delayed Margin Impact**: Current elevated spending is not reflected in margins due to large portions of investment being in **Construction in Progress (CIP)**, delaying depreciation expenses and their impact on earnings. [4][57] Financial Metrics - **Capex Contribution**: Hyperscalers are expected to account for **30% of Russell 1000 capex** from 2025 to 2027, doubling from **15% two years ago**. [14] - **CIP Growth**: ORCL's CIP grew by nearly **200%** over the past year, while AMZN and GOOGL reported increases of approximately **60%** and **40%**, respectively. [59][58] - **Capex-to-Sales Ratios**: Including finance leases, MSFT's capex-to-sales ratio is expected to increase from **28% to 38%**, and ORCL's from **41% to 58%** for FY26. [51] Investment Risks and Considerations - **Uncertain ROI**: While substantial investments are being made, the ultimate return on investment remains uncertain, particularly for data center assets with long useful lives. [3] - **Replacement Cycles**: The chips powering AI workloads require replacement every **5-6 years**, indicating a recurring capital commitment if demand remains strong. [3] - **Lease Commitments**: Lease commitments have rapidly increased, with ORCL's growing by **230%** and META's by over **300%** from FY24 to 1QFY26, indicating a potential future impact on expenses. [48] Additional Insights - **Analyst Revisions**: Consensus estimates for capex are being revised upward, with an average increase of **90%** from a year ago across the five major hyperscalers. [33] - **Finance Lease Strategy**: MSFT and ORCL are the largest users of finance leases, with MSFT's finance leases increasing by **76%** in FY2025. [42] - **CIP and Depreciation**: The rising CIP balance indicates a delay between capital outlay and expense recognition, affecting net income timing. [58][59] This summary encapsulates the critical insights and financial metrics discussed in the conference call, highlighting the ongoing investment trends and potential risks within the hyperscaler industry.

RT zain (@zainbacchus).@heliuslabs is hiring for a Full Stack Tech Lead.If you know someone in your network that would be a good fit please give me a shout. Happy to grab time sync to share why Helius is an asymmetric opportunity and has the leverage to drive market leadership.High-ownership, high-impact role, for someone who wants to play to win. ...

Core Viewpoint - The S&P 500 index has shown resilience and strength over the years, making it a favorable long-term investment opportunity, particularly through the SPDR S&P 500 ETF Trust, which has low fees and high liquidity [2][3][12]. Investment Performance - The S&P 500 has delivered an average annual return of 10% since its inception in the 1950s, indicating a strong historical performance [3]. - The index has recently recovered from earlier concerns related to tariffs and has reached new record highs, benefiting investors who held shares in S&P 500 index funds [2]. ETF Characteristics - The SPDR S&P 500 ETF Trust, launched over 30 years ago, is the first U.S.-listed ETF and is currently the most-traded ETF worldwide, with approximately 57 million shares traded daily [5]. - The ETF has a low expense ratio of 0.09%, making it an attractive option for investors looking to maximize gains while minimizing costs [6]. Diversification Benefits - Investing in the SPDR S&P 500 ETF provides instant diversification across 500 top companies, which can help mitigate risks associated with individual stocks [7][8]. - The index includes companies from various industries, ensuring exposure to strong players even during challenging economic times [9][11]. Current Holdings and Market Position - Technology stocks represent about 33% of the ETF, with major holdings including Nvidia, Microsoft, and Apple, each with weightings exceeding 6% [10]. - The index is rebalanced quarterly, ensuring that investors are always exposed to the most powerful companies in the market [10]. Investment Accessibility - Shares of the SPDR S&P 500 ETF can be purchased for approximately $660, making it accessible for investors looking to invest less than $1,000 [12].

Company Overview - Vertex Pharmaceuticals is a leading biotech company specializing in treatments for cystic fibrosis (CF) and has seen significant revenue growth since introducing CFTR modulators in 2012, with stock climbing approximately 190% over the past decade [5][13] - The company has successfully developed Trikafta, a treatment effective for up to 90% of CF patients, and recently launched Alyftrek, which addresses an additional 31 mutations, enhancing treatment efficacy [7][8] Revenue Drivers - Trikafta continues to be a major revenue driver for Vertex, while Alyftrek is expected to contribute significantly as it gains traction in the market [8] - Vertex has expanded its portfolio with the launch of Casgevy for blood disorders and Journavx for pain management, both of which are anticipated to become substantial revenue sources [9][11] Pipeline and Future Prospects - Vertex has four programs in pivotal development, including candidates for kidney diseases and type 1 diabetes, which are nearing regulatory review [12] - The company is well-positioned to expand its commercialized drugs and treatment areas, supported by the ongoing strength of its CF program, indicating strong potential for future revenue growth [13]

Chinese technology stocks listed in Hong Kong jump to their highest level in almost four years as optimism over AI fueled demand https://t.co/NknSRB1lM9 ...

Not that long ago, pretty much everybody assumed that the next non- tech stock to cross the trillion dollar threshold would be the stock of Eli Lilly. Why not. They developed a weight loss and diabetes wonder drug with incredible prospects.Oh, but this market plays many tricks on us every day, including today where the Dow dipped 126 points, estimate declined.13%, and the Nasdaq edged down 007%. The anomaly this time, it looks like the next trillion dollar stock won't be Eli Lilly. If anything, it's more li ...